Literature DB >> 33679328

Emerging Perspectives on Dipeptide Repeat Proteins in C9ORF72 ALS/FTD.

Alexander Schmitz1,2, João Pinheiro Marques1,2,3, Irina Oertig1,2, Niran Maharjan1,2, Smita Saxena1,2.   

Abstract

The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide expansion in the chromosome 9 open reading frame 72 gene (C9ORF72). This hexanucleotide expansion consists of GGGGCC (G4C2) repeats that have been implicated to lead to three main modes of disease pathology: loss of function of the C9ORF72 protein, the generation of RNA foci, and the production of dipeptide repeat proteins (DPRs) through repeat-associated non-AUG (RAN) translation. Five different DPRs are currently known to be formed: glycine-alanine (GA) and glycine-arginine (GR) from the sense strand, proline-alanine (PA), and proline-arginine (PR) from the antisense strand, and glycine-proline (GP) from both strands. The exact contribution of each DPR to disease pathology is currently under intense scrutiny and is still poorly understood. However, recent advances in both neuropathological and cellular studies have provided us with clues enabling us to better understand the effect of individual DPRs on disease pathogenesis. In this review, we compile the current knowledge of specific DPR involvement on disease development and highlight recent advances, such as the impact of arginine-rich DPRs on nucleolar protein quality control, the correlation of poly-GR with neurodegeneration, and the possible involvement of chimeric DPR species. Further, we discuss recent findings regarding the mechanisms of RAN translation, its modulators, and other promising therapeutic options.
Copyright © 2021 Schmitz, Pinheiro Marques, Oertig, Maharjan and Saxena.

Entities:  

Keywords:  C9ORF72 ALS/FTD; RAN translation; amyotrophic lateral scelerosis; dipeptide repeat proteins (DPRs); motor neuron; neurodegeneration

Year:  2021        PMID: 33679328      PMCID: PMC7930069          DOI: 10.3389/fncel.2021.637548

Source DB:  PubMed          Journal:  Front Cell Neurosci        ISSN: 1662-5102            Impact factor:   5.505


  10 in total

Review 1.  Antisense Oligonucleotides for the Study and Treatment of ALS.

Authors:  Benjamin D Boros; Kathleen M Schoch; Collin J Kreple; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2022-06-02       Impact factor: 6.088

2.  Interactome screening of C9orf72 dipeptide repeats reveals VCP sequestration and functional impairment by polyGA.

Authors:  Janja Božič; Helena Motaln; Anja Pucer Janež; Lara Markič; Priyanka Tripathi; Alfred Yamoah; Eleonora Aronica; Youn-Bok Lee; Raphael Heilig; Roman Fischer; Andrew J Thompson; Anand Goswami; Boris Rogelj
Journal:  Brain       Date:  2022-04-18       Impact factor: 15.255

3.  Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD.

Authors:  Gopinath Krishnan; Denitza Raitcheva; Daniel Bartlett; Mercedes Prudencio; Diane M McKenna-Yasek; Catherine Douthwright; Björn E Oskarsson; Shafeeq Ladha; Oliver D King; Sami J Barmada; Timothy M Miller; Robert Bowser; Jonathan K Watts; Leonard Petrucelli; Robert H Brown; Mark W Kankel; Fen-Biao Gao
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

Review 4.  Proteinopathies associated to repeat expansion disorders.

Authors:  Anthony Fourier; Isabelle Quadrio
Journal:  J Neural Transm (Vienna)       Date:  2022-01-24       Impact factor: 3.575

Review 5.  Dysfunction of RNA/RNA-Binding Proteins in ALS Astrocytes and Microglia.

Authors:  Simona Rossi; Mauro Cozzolino
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 6.  Dihedral Angle Measurements for Structure Determination by Biomolecular Solid-State NMR Spectroscopy.

Authors:  Patrick C A van der Wel
Journal:  Front Mol Biosci       Date:  2021-12-06

7.  Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation.

Authors:  Feilin Liu; Dmytro Morderer; Melissa C Wren; Sara A Vettleson-Trutza; Yanzhe Wang; Benjamin E Rabichow; Michelle R Salemi; Brett S Phinney; Björn Oskarsson; Dennis W Dickson; Wilfried Rossoll
Journal:  Acta Neuropathol Commun       Date:  2022-02-14       Impact factor: 7.801

Review 8.  The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD.

Authors:  Pegah Masrori; Jimmy Beckers; Helena Gossye; Philip Van Damme
Journal:  Mol Neurodegener       Date:  2022-03-18       Impact factor: 14.195

9.  PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD.

Authors:  Federica Pilotto; Alexander Schmitz; Niran Maharjan; Rim Diab; Adolfo Odriozola; Priyanka Tripathi; Alfred Yamoah; Olivier Scheidegger; Angelina Oestmann; Cassandra N Dennys; Shrestha Sinha Ray; Rochelle Rodrigo; Stephen Kolb; Eleonora Aronica; Stefano Di Santo; Hans Rudolf Widmer; Nicolas Charlet-Berguerand; Bhuvaneish T Selvaraj; Siddharthan Chandran; Kathrin Meyer; Benoît Zuber; Anand Goswami; Joachim Weis; Smita Saxena
Journal:  Acta Neuropathol       Date:  2022-09-19       Impact factor: 15.887

Review 10.  A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.

Authors:  Georgios Pampalakis; Georgios Angelis; Eleni Zingkou; Kostas Vekrellis; Georgia Sotiropoulou
Journal:  Clin Transl Med       Date:  2022-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.